Deferoxamine Mesylate Injection, Powder, Lyophilized, For Solution
Product Images NDC 68083-172

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Deferoxamine Mesylate (NDC 68083-172). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image2g (Deferoxamine 2g)

Label for Deferoxamine Mesylate for Injection, USP, 2 g per vial, lyophilized powder for solution. Indicated for subcutaneous, intramuscular, or intravenous use. Single-dose vial. Manufactured by Gland Pharma Limited, Hyderabad, India. Includes storage instructions and a barcode.*

FDA Label Image

Deferoxamine01 (Deferoxamine01)

Chemical structure of Deferoxamine mesylate showing its molecular formula with multiple amide and hydroxamic acid groups, along with the methanesulfonic acid (mesylate) component.*

FDA Label Image

Image02 (Deferoxamine02)

Label for Deferoxamine Mesylate for Injection, USP, 500 mg per vial. The lyophilized powder injection is indicated for subcutaneous, intramuscular, or intravenous use. Manufactured by Gland Pharma Limited, Hyderabad, India. The label includes storage instructions to keep between 20° to 25°C and cautions against use of turbid solutions. Bar code and lot/expiration placeholders are present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.